Sage Therapeutics Inc (FRA:SG7)
€ 5.79 -0.394 (-6.37%) Market Cap: 328.82 Mil Enterprise Value: -195.46 Mil PE Ratio: 0 PB Ratio: 0.70 GF Score: 45/100

SAGE Therapeutics Inc FutureCast: An R&D and Portfolio Review Transcript

Dec 14, 2021 / 01:00PM GMT
Release Date Price: €34.54 (+2.16%)
Helen Rubinstein
Sage Therapeutics, Inc. - IR Officer

Good morning everyone and thanks for joining the third annual Sage FutureCast and R&D portfolio review event. I'm Helen Rubinstein, Investor Relations at Sage.

Before we begin, I encourage everyone to go to the Investor and Media section of our website at sagerx.com, where you can find the press release related to today's call as well as the slides that we will discuss. I'd like to point out that we will be making forward-looking statements on today's call, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties and our actual results may differ materially. Please consult the risk factors discussed in today's press release and in our SEC filings for additional details.

I'll now turn the call over to Barry Greene, our Chief Executive Officer for opening remarks.

Barry E. Greene
Sage Therapeutics, Inc. - President, CEO & Director

Hi, everyone. Thanks for joining us today and welcome to our third annual FutureCast and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot